IP Library Granted Patent US 11,191,739
Granted Patent B2
US 11,191,739 · App. 17/192,192 · Granted Dec 7, 2021

Bupropion as a modulator of drug activity

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/138A61K9/0053A61K31/137A61K31/485A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,191,739
App. No.
17/192,192
Granted
Dec 7, 2021
Kind
B2
Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claims (25)

1. A dosage form comprising:

about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide; or

an amount of a bupropion in the free base form or a salt form and an amount of a dextromethorphan in the free base form or a salt form that provides about the same AUC 0-12 of bupropion and about the same AUC 0-12 of dextromethorphan in a human being as administering: about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide to the human being.

2. The dosage form of claim 1 , comprising about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide.

3. The dosage form of claim 1 , wherein the dextromethorphan is formulated for immediate release.

4. The dosage form of claim 1 , wherein the bupropion is formulated for sustained release.

5. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 1 to a human being.

6. The method of claim 5 , wherein the dosage form is administered orally.

7. The method of claim 5 , wherein the dosage form is administered once daily.

8. The method of claim 5 , wherein the dosage form is administered twice daily.

9. The method of claim 5 , wherein the dosage form is administered for at least 8 consecutive days.

10. The method of claim 5 , wherein the dosage form is administered for at least 14 consecutive days.

11. The method of claim 5 , wherein the dosage form is administered for at least 30 consecutive days.

12. A dosage form comprising:

about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide; or

an amount of a bupropion in the free base form or a salt form and an amount of a dextromethorphan in the free base form or a salt form that provides about the same AUC 0-24 of bupropion and about the same AUC 0-24 of dextromethorphan in a human being as administering: about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide to the human being.

13. The dosage form of claim 12 , comprising about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide.

14. The dosage form of claim 12 , wherein the dextromethorphan is formulated for immediate release.

15. The dosage form of claim 12 , wherein the bupropion is formulated for sustained release.

16. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 12 to a human being.

17. The method of claim 16 , wherein the dosage form is administered orally.

18. The method of claim 16 , wherein the dosage form is administered once daily.

19. The method of claim 16 , wherein the dosage form is administered for at least 8 consecutive days.

20. The method of claim 16 , wherein the dosage form is administered for at least 14 consecutive days.

21. The method of claim 16 , wherein the dosage form is administered for at least 30 consecutive days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 056261/0190 →